Bio-thera solutions pipeline
Web2024-11-27 Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA) 2024-09-25 Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China
Bio-thera solutions pipeline
Did you know?
WebDec 2, 2024 · Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune,... Web2024-09-27 Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2024, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2; 2024-08-02 Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8009, an Antibody Drug Conjugate Targeting B7-H3 (CD276) for the Treatment of Advanced …
WebSep 8, 2024 · Bio-Thera Solutions, Ltd. is a biopharmaceutical company located in Guangzhou, China, and dedicated to research and development into novel therapeutics, as well as biosimilars to treat a... WebDec 2, 2024 · Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, announced that Jin-Chen Yu, SVP, Research will present a talk on BAT8009 at the 2nd Annual ADC Target Selection Summit taking place December 6 - 8, 2024 in Boston, MA.
WebMar 27, 2024 · Bio-Thera Solutions is a clinical-stage biopharmaceutical company focused on innovative therapeutics and biosimilars. Bio-Thera is developing a pipeline of ADCC-enhanced monoclonal antibodies, antibody-drug conjugates and best-in-class antibodies for the treatment of a broad range of cancers and other diseases. Bio-Thera’s biosimilar … WebNov 8, 2024 · 01 Nov 2024 Bio-Thera Solutions announces intention to submit BLA/MAA to NMPA, FDA, EMA and other regulatory bodies around the world for Autoimmune disorder. 19 Oct 2024 Phase-III clinical trials in Plaque psoriasis in Hungary (SC) (EudraCT2024-001770-59) (NCT05377944) 19 May 2024 Phase-I clinical trials in Autoimmune disorders …
Web2024-06-20 NMPA Accepts Bio-Thera Solutions' Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin® 2024-02-03 Bio-Thera Solutions Announces Positive Top-Line Results for BAT1706, A Proposed Biosimilar to Avastin® 2024-01-10 Bio-Thera Solutions Launches First Commercial Product, QLETLI® (格乐立®), in China
WebJun 8, 2024 · “Bio-Thera is focused on developing and commercializing a pipeline of safe, effective and affordable biosimilars and is proud to be one step closer to bringing a … cities that start with k in iowaWebThrough this full-time, 11-week, paid training program, you will have an opportunity to learn skills essential to cyber, including: Network Security, System Security, Python, … cities that start with laWebDec 2, 2024 · Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, announced … diary of the wimpy kid orderWebJun 9, 2024 · Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to … diary of the wimpy kid new movieWebJun 3, 2024 · Bio-Thera Solutions Cautionary Note Regarding Forward-Looking Statements. This news release contains certain forward-looking statements relating to … cities that start with l in texasWeb2 hours ago · 4D Molecular Therapeutics, Inc. (FDMT) shares rallied 11.2% in the last trading session to close at $16.85. This move can be attributable to notable volume with … diary of the wimpy kid pdf freeWeb2024-01-24 Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors; 2024-12-30 Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026, a Monoclonal Antibody Targeting OX40 diary of the wimpy kid rodrick